ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Neurology · Lancet · 2026-05-30

In 586 people with early-stage Parkinson's disease on stable symptomatic medication, intravenous prasinezumab did not significantly delay confirmed motor progression versus placebo (HR 0·84, 95% CI 0·69–1·01; p=0·066); serious adverse events 12% in both groups.

RCTn = 586
Nikolcheva et al. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.